Precise hepatectomy in the treatment of patients with primary liver cancer

Abstract

Primary liver cancer is a commonly seen tumor, and early surgical resection can achieve a favourable effect, however traditional laparotomy has the shortcomings of great trauma and multiple postoperative complications, which are not beneficial to the recovery of patients. To explore the characteristics and effectiveness of precise hepatectomy, 116 patients with primary liver cancer who were admitted to Chenzou No. 1 People’s Hospital, Hunan, China, between August 2015 and December 2016 were selected. They were randomly divided into a conventional hepatectomy group and a precise hepatectomy group, 58 in each group. The surgical condition, changes of liver function indexes, prognosis and incidence of postoperative complications were observed and compared between the two groups. The results suggested that patients who underwent precise hepatectomy had less average intraoperative bleeding and shorter hospital stay compared to those who underwent conventional hepatectomy, but the duration of the surgery was longer (P < 0.05). Compared to pre-surgery, the content of total bilirubin in serum (TBIL), alanine transaminase (ALT) and aspartate transaminase (AST) of the two groups decreased, and the content of albumin (ALB) increased after treatment. The changes of the indexes of the precise hepatectomy group were more obvious, and the liver function of was superior to that of the conventional hepatectomy group; the comparison within group and between groups had statistical significance (P<0.05). The recurrence rate of tumor of the precise hepatectomy group was significantly lower than that of the conventional hepatectomy group (P<0.05). The lesion removal rate, one-year survival rate, and two-year survival rate of the former were obviously higher than that of the latter (P<0.05). The difference of the incidence of complications between the two groups had statistical significance (P<0.05). Precise hepatectomy has a favourable effect in the treatment of primary liver cancer as it can effectively control cancer recurrence and improve prognosis; hence it is worth promotion.